No, Do Not Give Another Loading Dose of Levetiracetam
If seizures persist after an initial loading dose of levetiracetam, you should switch to a different second-line antiseizure medication (fosphenytoin or valproate) rather than administering another dose of levetiracetam. The evidence shows that levetiracetam only terminates seizures in approximately 47% of patients with benzodiazepine-refractory status epilepticus, and there is no data supporting repeat loading doses 1.
The Evidence-Based Approach
Why Not Repeat Levetiracetam
The 2024 ACEP guidelines, based on the landmark ESETT trial, clearly demonstrate that:
- Levetiracetam terminates seizures in only 47% of benzodiazepine-refractory status epilepticus cases 1
- All three second-line agents (levetiracetam, fosphenytoin, valproate) have equivalent efficacy at approximately 45-47% 1
- The FDA labeling for Keppra provides no guidance on repeat loading doses for persistent seizures 2
What You Should Do Instead
Switch to an alternative second-line agent:
- Fosphenytoin - equivalent efficacy to levetiracetam but with slightly higher risk of hypotension (3.2% vs 0.7%) 1
- Valproate - equivalent efficacy with intermediate safety profile (1.6% hypotension risk) 1
The guideline explicitly states that emergency physicians should treat benzodiazepine-refractory seizures with "a second-line agent" - meaning one agent from the three options, not sequential doses of the same medication 1.
Critical Dosing Information for Initial Loading
If you haven't yet given the optimal initial dose, the FDA-approved loading dose is:
- Adults: 1000-1500 mg IV (approximately 20-30 mg/kg for average-weight adults) 2
- Maximum studied dose: 60 mg/kg up to 4500 mg 3
However, research shows that higher loading doses (≥40 mg/kg) do not improve seizure termination rates and are associated with significantly higher intubation rates (45.8% vs 26.8-28.2% for lower doses) 3.
Important Caveats
The 60-Minute Rule
The ESETT trial measured outcomes at 60 minutes post-infusion 1. If seizures persist beyond this timeframe after levetiracetam, the medication has failed and you need to escalate therapy, not repeat it.
Safety Considerations
- Levetiracetam has the best safety profile among second-line agents (0.7% hypotension, 0.7% arrhythmias, 20% intubation rate) 1
- This favorable safety profile does not justify repeat dosing when the medication has already failed
Progression to Refractory Status Epilepticus
If seizures continue despite two appropriately dosed second-line agents, the patient has refractory status epilepticus and requires:
- ICU-level care
- Continuous EEG monitoring
- Third-line agents (midazolam, propofol, or pentobarbital infusions)
- Possible intubation for airway protection
The Bottom Line
The evidence strongly supports using levetiracetam as one attempt at seizure termination in benzodiazepine-refractory status epilepticus. If it fails, switch to fosphenytoin or valproate rather than giving more levetiracetam. The 47% success rate means that roughly half of patients will need an alternative agent, and there is no evidence that additional levetiracetam dosing improves outcomes 1.